BriaCell Therapeutics Corp.
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
(0.0% 1d) (-3.2% 1m) (-61.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 34,999,980
https://www.briacell.com
Sec Filling | Patents | 2022 employees
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
cancer
add to watch list Paper trade email alert is off
SmartRent Inc - Ordinary Shares - Class A
SMRT
new
|
$
0%
|
Professional, Scientific, and T...
(0% volume)
Earnings Calendar:
Market Cap:
Sec Filling | Patents | n/a employees
add to watch list Paper trade email alert is off
Tharimmune Inc
THAR
new
|
$
0%
|
Professional, Scientific, and T...
(0% volume)
Earnings Calendar:
Market Cap:
Sec Filling | Patents | n/a employees
add to watch list Paper trade email alert is off
TriSalus Life Sciences Inc
TLSI
new
|
$
0%
|
Professional, Scientific, and T...
(0% volume)
Earnings Calendar:
Market Cap:
Sec Filling | Patents | n/a employees
add to watch list Paper trade email alert is off
Tourmaline Bio Inc
TRML
new
|
$
0%
|
Professional, Scientific, and T...
(0% volume)
Earnings Calendar:
Market Cap:
Sec Filling | Patents | n/a employees
add to watch list Paper trade email alert is off
Tevogen Bio Holdings Inc.
TVGN
new
|
$
0%
|
Professional, Scientific, and T...
(0% volume)
Earnings Calendar:
Market Cap:
Sec Filling | Patents | n/a employees
add to watch list Paper trade email alert is off
Biomea Fusion Inc
BMEA | $10.83 -0.18% 0.09% 600K
|
Professional, Scientific, and T...
(0.0% 1d) (-29.3% 1m) (-63.9% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-54.26% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 388,681,769
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees
Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.
genetic cancer msa
add to watch list Paper trade email alert is off
Clinuvel Pharmaceuticals Ltd
CLVLY
|
$9.19
-3.26%
31.84%
3.4K
|
Professional, Scientific, and T...
(0.0% 1d) (1.8% 1m) (-31.3% 1y) (0.0% 2d) (0.0% 3d) (-3.3% 7d) (35.03% volume)
Earnings Calendar:
Market Cap: $ 460,669,611
https://www.clinuvel.com/
Sec Filling | Patents | n/a employees
(AU)
add to watch list Paper trade email alert is off
Compass Therapeutics Inc
CMPX
|
$1.49
1.36%
0.0%
110K
|
Professional, Scientific, and T...
(0.0% 1d) (-27.3% 1m) (-48.8% 1y) (0.0% 2d) (0.0% 3d) (1.4% 7d) (-54.28% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 205,007,865
Sec Filling | Patents | 26 employees
compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond
add to watch list Paper trade email alert is off
Miromatrix Medical Inc
MIRO | $3.39 3.25% 630K
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (152.9% 1y) (0.0% 2d) (0.0% 3d) (0.6% 7d) (273.61% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 92,951,183
Sec Filling | Patents | 37 employees
miromatrix medical inc. is a life science company that has a novel and proprietary technology to remove cells from, or decellularize, organs and tissues from animal and human sources, facilitating the creation of numerous products, including the potential of fully biological transplantable human organs.
t-cell
add to watch list Paper trade email alert is off
Graphite Bio Inc
GRPH
4
|
$3.27
1.84%
490K
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (7.4% 1y) (0.0% 2d) (-2.8% 3d) (0.0% 7d) (-33.57% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 190,434,748
https://graphitebio.com
Sec Filling | Patents | 27 employees
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
gene therapies
add to watch list Paper trade email alert is off
Impel NeuroPharma Inc.
IMPL 4 | $0.2411 -77.19% 860K
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (-76.6% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees
(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
parkinson treatment
add to watch list Paper trade email alert is off
Prometheus Biosciences Inc
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (2.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-47.11% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 9,558,822,541
https://www.prometheusbiosciences.com
Sec Filling | Patents | n/a employees
Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.
diagnostics gastrointestinal treatment
add to watch list Paper trade email alert is off
VectivBio Holding AG
VECT | $16.85 0.12% 130K
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (46.6% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (-48.24% volume)
Earnings Calendar:
Market Cap: $ 1,057,156,615
https://vectivbio.com
Sec Filling | Patents | 32 employees
VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).
msa gastrointestinal treatment
add to watch list Paper trade email alert is off
FRONTERA GROUP INC.
FRTG
|
$0.0003
96.05%
15K
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (-94.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-70.0% volume)
Earnings Calendar:
Market Cap: $ 23,219
Sec Filling | Patents | 1 employees
frontera group is a multi-specialist service group. we believe that a better understanding of the patient experience is necessary to achieve brand or corporate differentiation. our services immerse you in the world of the patient, so that: - your strategies are driven by the people you treat (redline strategic) - the patient voice can be heard loud and clear throughout your communication (frontera london) - your mobile health solutions yield better outcomes (stikke) from copd to leukaemia, rheumatology to rare diseases, our innovative products help put the patient perspective at the heart of your approach.
communication
add to watch list Paper trade email alert is off
MediXall Group, Inc.
MDXL
|
$0.0009
72100.0%
470
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (50.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-52.7% volume)
Earnings Calendar:
Market Cap: $ 117,198
https://medixall.com/
Sec Filling | Patents | 19 employees
(US) the mission of the medixall group is to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. by approaching the healthcare ecosystem as a whole, medixall creates, invests and incubates companies that embody its mission statement. the first product medixall is developing is the medixall healthcare marketplace. the medixall platform is a new generation healthcare marketplace platform to address the growing need of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. with medixall, patient/clients find price transparency and the ability to make informed choices based on price, location and schedule for requested medical products and services. by delivering a solution that better connect consumers with high-quality healthcare providers and wellness services, medixall enable healthcare providers to en
communication
add to watch list Paper trade email alert is off
TORtec Group Corp
TRTK
|
$0.01
102400.0%
130
|
Professional, Scientific, and T...
(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-44.4% volume)
Earnings Calendar:
Market Cap: $ 1,000,749
http://tortec.group/
Sec Filling | Patents | n/a employees
(US)
add to watch list Paper trade email alert is off
Quality Online Education Group Inc.
QOEG | $0.002 3020.0% 16K
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (-88.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (1472.8% volume)
Earnings Calendar:
Market Cap: $ 3,710,131
Sec Filling | Patents | 30 employees
(HK) quality online education group inc. is a leading e- learning company that provides comprehensive online lessons to students in different parts of the world. we are the pioneer and leader of providing real-time online small group classes. we deliver quality education to students and noticeable results from our passionate teachers and teaching assistants. with our ai system, we combined education and entertainment (edu-tertainment) in part of the learnings. it is our mission to develop confidence in our students so they can reach their goals with happiness and efficiency!
education
add to watch list Paper trade email alert is off
PREDICTIVE TECHNOLOGY GROUP, INC.
PRED
|
$0.0005
13800.0%
20K
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (66.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-92.86% volume)
Earnings Calendar:
Market Cap: $ 450,000
Sec Filling | Patents | 63 employees
predictive technology group, inc., a salt lake city, ut therapeutics and life sciences company, is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique novel gene-based diagnostics, biotechnology treatments and companion therapeutics. through its' wholly owned subsidiaries, predictive therapeutics and predictive biotech, the company focuses on four main clinical categories: endometriosis, scoliosis, degenerative disc disease and regenerative human cell and tissue products. in addition to predictive biotech's efforts to advance regenerative medicine, predictive therapeutics is committed to assisting women in overcoming the devastating consequences of endometriosis via appropriate early-stage diagnosis and subsequent treatment.
t-cell diagnostics
add to watch list Paper trade email alert is off
Cell Source, Inc.
CLCS
|
$0.398
15.25%
2.1K
|
Professional, Scientific, and T...
(0.0% 1d) (-32.5% 1m) (132566.7% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (-83.4% volume)
Earnings Calendar:
Market Cap: $ 16,325,701
Sec Filling | Patents | 1 employees
marrow cell source , has been started with the aim to cater to patients who required a matched bone marrow sample. indian gene pool requires a bone marrow registry
t-cell
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Last 48 Hours Insiders Buying
MCFT P 26039 | $21.5 1.9% 1.86% 110K
|
Consumer Durables
|
00:00
YORW P 29 | $35.42 1.0% 1.02% 66K
|
Utilities
|
19:01
VUZI P 14500 | $1.35 11.57% 10.37% 840K
|
Electronic Technology
|
17:00
BANF P 256 | $91.28 2.24% 2.18% 150K
|
Finance
|
15:30
RMCF | $3.57 0.56% 0.28% 11K
|
Consumer Non-Durables
|
20:10